ASTS
10 August EX-99.1
AST SpaceMobile
150 to 200 million FY26 guide
AST sells the array. The guide is 150 to 200 million for fiscal 2026. The array is 20,000 square feet on BlueBirds 11 to 13.
The Long Read · 22 Aug
United Therapeutics is paying Varda to grow crystals in orbit, and the product that lands is still a vial.
United Therapeutics, 13 May, contracted Varda to crystallize pulmonary small molecules on W-series capsules.
Thesis map
AST SpaceMobile sells a phone array. Starlink sells text. Amazon Leo is about 391 satellites under a 5 June penalty. They are not one industry.
AST SpaceMobile printed 13 satellites on 5 August, BlueBirds 11 to 13, 20,000 square feet of array. The 10 August EX-99.1 named 60-plus mobile operators, 3 billion subscribers on paper, a 1.30 billion dollar backlog, and a 150 to 200 million dollar fiscal 2026 guide. Starlink already sells text. Rocket Lab bid 8 billion dollars for Iridium on 29 June.
The chain
- 01
AST array
Thirteen satellites on 5 August. The array is the product. Text is not the array.
- 02
Starlink text
Starlink already sells text. Direct-to-phone messaging is not consumer broadband to an unmodified phone. 650-plus birds in 22 countries is the messaging network, not an AST array.
- 03
Amazon Leo
Amazon Leo is about 391 satellites under a 5 June penalty. That is a constellation under a clock, not an AST array.
- 04
Paper backlog
Sixty-plus mobile operators and 3 billion subscribers on paper. A backlog is not unmodified-phone broadband at a postpaid price.
Long side
Owns the scarce object. Named filing, named plant, named queue.
IRDM
Rocket Lab, 29 June
Iridium
8 billion dollar bid
Rocket Lab bid 8 billion dollars for Iridium on 29 June and does not close until mid-2027. That is the old bid, not an AST array.
long
Mobile operators
60-plus on paper
Sixty-plus mobile operators sit on the 10 August exhibit. Paper subscribers are 3 billion. Paper is not a filled SIM.
RKLB
Rocket Lab
Iridium close mid-2027
Rocket Lab is the bidder on Iridium. Neutron window narrowing sits on the same pulse. A launch company is not an array company.
Short side
Constrained by the chain, or a substitute that is not the product.
short
One industry slide
A cashtag treats AST arrays, Starlink text, Amazon Leo, and an Iridium bid as one space-mobile trade. They are four products.
short
Postpaid substitute
Text is not broadband. Consumer broadband to unmodified phones at a price that replaces terrestrial postpaid has not printed.
short
Satellite count
13 vs 45 by June 2027
Thirteen satellites on 5 August is not 45 operational BlueBirds by 30 June 2027. Count is a clock, not the product.
short
2028 file
Amazon-Globalstar
about 11 billion, 5,105 D2D
The Amazon-Globalstar file is about 11 billion dollars, 5,105 satellites, direct-to-device, 2028. Amazon Leo under a 5 June penalty is not that file. Do not merge them.
How they interconnect
Starlink textis notAST array
Starlink text is not an AST array. Twenty thousand square feet of BlueBird is not a messaging-first network.
AST arrayis notAmazon Leo
An AST array is not Amazon Leo under a 5 June penalty. About 391 satellites is a different clock.
AST arrayis not yetPaper backlog
An array on 13 satellites is not a 1.30 billion dollar backlog of unmodified-phone broadband. Paper operators still have to fill.
AST SpaceMobilesellsAST array
AST SpaceMobile sells the array. The FY26 guide is 150 to 200 million dollars. That is the listed product.
IridiumpredatesStarlink text
Iridium predates Starlink text. An 8 billion dollar bid on 29 June is the old constellation changing hands, not a new array.
Mobile operatorssits inPaper backlog
Sixty-plus operators sit in the 10 August backlog. Three billion subscribers are on paper until a SIM is unmodified-phone broadband.
Rocket Labbids forIridium
Rocket Lab bids 8 billion dollars for Iridium, close mid-2027. That interconnect is a launch company buying the old bid.
One industry slideflattensStarlink text
One industry slide flattens text into the array. Direct-to-phone, dish internet, and a messaging-first network are not one trade.
AST SpaceMobileis not yetPostpaid substitute
AST is not yet a postpaid substitute. Unmodified-phone broadband at a replacing price has not printed.
AST SpaceMobilestill short ofSatellite count
Thirteen satellites are still short of 45 operational BlueBirds by 30 June 2027. The count clock is live.
Amazon Leois notAmazon-Globalstar
Amazon Leo under a 5 June penalty is not the Amazon-Globalstar file of about 11 billion dollars and 5,105 direct-to-device satellites. Do not merge them.
If you believe the thesis
Direct-to-phone is four products, not one industry. AST arrays are not Starlink text. Amazon Leo under a 5 June FCC priority penalty is not either. A cashtag treats them as one. The 10 August backlog is paper operators until unmodified-phone broadband replaces terrestrial postpaid.
If the thesis is incorrect
One listed name reports consumer broadband to unmodified phones at a price that replaces terrestrial postpaid. AST SpaceMobile having at least 45 operational BlueBirds on orbit by 30 June 2027 would spend the constellation-count leg. Rocket Lab closing Iridium in mid-2027 is a different product.
Space pharma has a thumbnail problem and a contract problem. The thumbnail is CNBC's June frame: SpaceX, Varda, and Redwire on one tile under the words space race pharma. The contract is the 13 May release naming United Therapeutics as the customer paying Varda to crystallize pulmonary small molecules on W-series vehicles, with Rocket Lab's Pioneer buses handling power, comms, and deorbit. Delian Asparouhov told Ars and CNBC in May and June that W-6 was already in orbit, three more capsules would fly in 2026, seven in 2027, and that the first large public pharmaceutical company was using its own balance sheet, not NASA, to make a product in microgravity. His line to the press was blunt: they send us a drug and we give them back a better drug. That sentence is either the opening of a new supply chain or a very expensive formulation experiment. The difference is not the crystal. It is whether anything in the vial ever enters a clinical protocol.
They send a drug. A landing has to send it back.
United Therapeutics is a pulmonary company with a balance sheet and a reason to care how a molecule sits in the lung. That is why the 13 May naming matters more than another ISS paper. NASA-funded station work produced publications. This contract is supposed to produce a better vial: improved stability and bioavailability on small molecules that matter to a lung franchise. Varda is a re-entry company that happens to carry a crystallizer. Rocket Lab already knows how to fly a Pioneer bus. The industrial tell is on RKLB's mission page, not on a pitch deck about orbital manufacturing.
What microgravity is for when someone is paying
Protein and small-molecule crystals that grow larger, or in a form that survives the bottle, are a real materials fact. They are also a formulation R&D fact. A crystal that looks better in a W-capsule is a candidate. Redwire's PIL-BOX heritage is still ISS kit work. SpaceMD has talked about 54 units, 37 compounds, and a move toward Vast or StarLab. Those remain kits and partnerships, not a return cadence with a listed buyer attached. Until United Therapeutics, or any named partner, discloses a space-grown form that enters an IND or a named bridging study, the nicer crystal is a poster with better photography.
The X feed is part of the evidence. The account that should have posted the 13 May release was busy with ASTS. That is information. Public pharma rarely buys orbital R&D for the timeline. It buys it when a formulation problem is expensive enough on Earth that a capsule flight is cheaper than another year of bench work.
Cadence is the P&L
Three more in 2026, seven in 2027, about 200 staff, $330 million raised: those are Asparouhov's numbers to the press, not ours. They define the only operational claim that is falsifiable before anyone talks about total addressable market. A Pioneer bus that flies, lands, and returns a vial on schedule is a product RKLB already sells into a niche. A Pioneer bus that slips twice while the press still says seven in 2027 is a schedule story, not a pharma story.
ISS retirement is the forcing function everyone cites. It does not automatically create a customer. It creates vacancy. United Therapeutics filled part of that vacancy with a check and a molecule class. That is one contract, one vehicle line, one return path. It is sample-return cadence: send up, grow, come home. The diagram on this page is honest about the loop. What happens after the landing is still United Therapeutics's problem on Earth.
What this does not say: that microgravity chemistry is fake, or that United Therapeutics is a space stock. United Therapeutics is a pulmonary stock that bought an experiment. Varda is private. The listed names in the chain are Rocket Lab as the bus, and whichever terrestrial tools you think hold the ordinary crystal analog. Thermo Fisher and Danaher are the boring comparables. Do not promote a capsule into a TAM because the thumbnail looked like one.
What would change the read
A United Therapeutics or named-partner disclosure that a space-crystallized candidate has entered a clinical protocol by 31 December 2027 is the confirm on the narrow claim. Seven successful W-class returns in 2027 is the cadence confirm, and it is Varda's number, not ours. We will count landings, not press releases. A year of slipped flights with no named molecule is the kill on sample-return as a business, not on microgravity as a science.
Extension matters more than hype. If United Therapeutics renews or expands after the first returns, the experiment graduated. If 2026 ends with one or two flights and the seven become three, space pharma stays a story about the station retiring while the vials stay on the bench. Rocket Lab wins either way on bus revenue. The question is whether anyone besides United Therapeutics writes a similar check.
The thesis is smaller than the thumbnail and larger than a single flight. Microgravity formulation is real. A named buyer with a return vehicle is new. An IND is still the line between R&D and revenue. Until that line crosses, treat Varda as a capsule company with a pharma customer, not as orbital manufacturing. Count the landings. Read the 8-Ks on Earth.
Do not promote a capsule into a TAM. United Therapeutics is a pulmonary stock that bought an experiment.